ST段抬高型心肌梗死伴非阻塞性冠状动脉及类似病变的死亡率
该研究基于3个中西部区域性STEMI项目的连续STEMI激活登记队列,回顾性分析8560例患者,其中阻塞性病变8151例(95.2%)、MINOCA 120例(1.4%)、MINOCA类似病变289例(3.8%)。中位随访7.1年,5年死亡率阻塞性病变16%、MINOCA 18%、类似病变18%,log-rank检验均无统计学显著差异(P=.29、P=.13)。校正Cox回归显示,MINOCA的5年死亡风险为阻塞性病变的1.93倍(95%CI 1.06-3.53),类似病变与阻塞性病变相似(HR 1.08;95%CI 0.79-1.49)。作者认为需进一步研究该高危STEMI人群的病理生理机制。
要点
- 连续STEMI队列8560例中,MINOCA占1.4%(120例)、MINOCA类似病变占3.8%(289例)、阻塞性病变占95.2%(8151例)。
- 5年死亡率:阻塞性病变16%(1228例)vs MINOCA 18%(20例;log-rank P=.29)vs 类似病变18%(52例;log-rank P=.13)。
- 校正Cox回归:MINOCA的5年死亡风险为阻塞性病变的1.93倍(95%CI 1.06-3.53);类似病变HR 1.08(95%CI 0.79-1.49)。
- MINOCA与类似病变患者出院时接受心脏药物的比例低于阻塞性病变。
- 作者认为需进一步研究该高危STEMI人群的病理生理机制。
适用人群与场景
- 3个中西部区域性STEMI项目的连续STEMI激活患者,数据自2003年3月至2020年12月。
- MINOCA定义:无罪犯动脉且肌钙蛋白升高,冠状动脉狭窄≤50%,并确认或怀疑冠状动脉斑块破裂、心外膜冠状动脉痉挛或冠状动脉栓塞/血栓。
- MINOCA类似病变:Takotsubo心肌病、心肌炎或非缺血性心肌病。
诊断标准与关键阈值
- MINOCA:无罪犯动脉、肌钙蛋白升高、无冠状动脉狭窄>50%,且确认或怀疑斑块破裂、心外膜冠状动脉痉挛或冠状动脉栓塞/血栓。
- MINOCA类似病变:Takotsubo心肌病、心肌炎或非缺血性心肌病。
- 阻塞性病变:作为对照的ST段抬高型心肌梗死伴阻塞性冠状动脉疾病。
研究设计与关键结果
- 回顾性分析前瞻性登记队列,连续STEMI激活患者8560例,来自3个区域性STEMI项目;平均(SD)年龄62(14)岁,女性30%(2609例),非西班牙裔白人94%(4358例)。
- 队列构成:阻塞性病变8151例(95.2%)、MINOCA 120例(1.4%)、MINOCA类似病变289例(3.8%)。
- 中位(IQR)随访7.1(3.6-10.7)年;MINOCA和类似病变患者出院时接受心脏药物的比例低于阻塞性病变。
- 5年死亡率:阻塞性病变16%(1228例)vs MINOCA 18%(20例;χ21=1.1;log-rank P=.29)vs 类似病变18%(52例;χ21=2.3;log-rank P=.13)。
- 校正Cox回归:与阻塞性病变相比,MINOCA的5年死亡风险高1.93倍(95%CI 1.06-3.53);类似病变HR 1.08(95%CI 0.79-1.49)。
证据类型、等级与局限
- 证据类型:回顾性分析前瞻性登记队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,MINOCA与阻塞性病变相比死亡风险更高(校正HR 1.93;95%CI 1.06-3.53),需进一步研究该高危STEMI人群的病理生理机制。
- MINOCA和MINOCA类似病变患者出院时接受心脏药物的比例低于阻塞性病变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The clinical characteristics and prognosis of patients with ST-segment elevation myocardial infarction (STEMI) with nonobstructive coronaries (MINOCA) are largely unknown.
OBJECTIVE: To assess differences in 5-year mortality in patients presenting with STEMI due to MINOCA and MINOCA mimickers as compared with obstructive disease.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis of a prospective registry-based cohort study of consecutive STEMI activations at 3 regional Midwest STEMI programs. STEMI without a culprit artery and elevated troponin levels were categorized as MINOCA (absence of coronary artery stenosis >50% and confirmed or suspected coronary artery plaque disruption, epicardial coronary spasm, or coronary embolism/thrombosis) or MINOCA mimickers (takotsubo cardiomyopathy, myocarditis, or nonischemic cardiomyopathy). Data were analyzed from March 2003 to December 2020.
MAIN OUTCOMES AND MEASURES: Adjusted Cox regression analysis was used to assess 5-year mortality risk in STEMI presenting with MINOCA and MINOCA mimickers in comparison with obstructive disease.
RESULTS: Among 8560 consecutive patients with STEMI, mean (SD) age was 62 (14) years, 30% were female (2609 participants), and 94% were non-Hispanic White (4358 participants). The cohort included 8151 patients with STEMI due to obstructive disease (95.2%), 120 patients with MINOCA (1.4%), and 289 patients with MINOCA mimickers (3.8%). Patients were followed up for a median (IQR) of 7.1 (3.6-10.7) years. Patients with MINOCA and MINOCA mimickers were less likely to be discharged with cardiac medications compared with obstructive disease. At 5-year follow-up, mortality in STEMI presenting with obstructive disease (1228 participants [16%]) was similar to MINOCA (20 participants [18%]; χ21 = 1.1; log-rank P = .29) and MINOCA mimickers (52 participants [18%]; χ21 = 2.3; log-rank P = .13). In adjusted Cox regression analysis compared with obstructive disease, the 5-year mortality hazard risk was 1.93 times higher in MINOCA (95% CI, 1.06-3.53) and similar in MINOCA mimickers (HR, 1.08; 95% CI, 0.79-1.49).
CONCLUSIONS AND RELEVANCE: In this large multicenter cohort study of consecutive clinical patients with STEMI, presenting with MINOCA was associated with a higher risk of mortality than obstructive disease; the risk of mortality was similar in patients with MINOCA mimickers and obstructive disease. Further investigation is necessary to understand the pathophysiologic mechanisms involved in this high-risk STEMI population.
参考来源
- Quesada O, Yildiz M, Henry TD, et al. Mortality in ST-Segment Elevation Myocardial Infarction With Nonobstructive Coronary Arteries and Mimickers. JAMA Netw Open. 2023. PMID: 37971742. doi:10.1001/jamanetworkopen.2023.43402
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。